A simple blood test to choose the best treatment for each patient with depression.

Informations projet

RxMine

N° de convention de subvention: 190160513

DOI

10.3030/190160513

Projet clôturé

Date de signature de la CE 15 Septembre 2022

Date de début 1 Juin 2022

Date de fin 31 Mai 2025

Financé au titre de

• The European Innovation Council (EIC)

Coût total

€ 3 570 000,00

Contribution de l’UE

€ 2 499 000,00

Coordonné par

GENETIKAPLUS LTD
Israel

Periodic Reporting for period 2 - RxMine (A simple blood test to choose the best treatment for each patient with depression.)

Période du rapport: 2023-06-01 au 2025-05-31

Résumé du contexte et des objectifs généraux du projet

Major depressive disorder is the largest contributor to the reduction of health-related quality of life globally, with up to 14 years of life lost per patient. It affects 300M people globally and was the 2nd leading cause of disability in 2020, contributing to 917 accumulated years lost per 100k people and costing up to €170 billion per year to the EU. Nevertheless, 63% of people suffering from depression do not receive adequate treatment due to the heterogeneity of the disease, uniquely affecting each individual with highly varied responses to treatments. When choosing a drug for treatment, the physician must choose from over 70 different medications and combinations. As each drug takes 4-6 weeks to test the patient loses months to years of their lives to disability and suffering or risking suicide (15% commit suicide) in the process of searching for the right treatment. This trial-and-error process costs patients’ lives, physician's time and payer's and the government's major costs. Precision mental health treatment is urgently needed.
RXMine is the first decision support tool for personalized treatment of depression with a simple blood sample: it matches each patient with the right antidepressant saving patient lives, physician time and payer costs.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

GenetikaPlus has made significant scientific achievements in the last 12 months. These include:
• Structuring the first 3-pillared AI-based technology that a integrates, DNA, patient history and neurobiological models and predicts evidence-based drug recommendation. This technology could help doctors to identify new treatments for a variety of diseases, as it would allow them to analyze large amounts of data and identify patterns that would be difficult to spot with the naked eye.
• Expanding multiple clinical trials within the US and Israel that have boosted the company's research and activity. These trials have helped GenetikaPlus to gather valuable data about the effectiveness of its products and services, and they have also helped to raise awareness of the company's work.
• Developed the initial user interface for our physician platform, preparing us for market launch of our product.
• Securing CE-IVD, HIPAA and GDPR compliance levels. This was accompanied by advances in our QMS/GLP implementation and QA documentation. This means that GenetikaPlus's products and services meet the highest standards of quality and security and that they can be used in clinical settings.
• Expanding our platform to include analysis of more than 30 drugs. This has helped GenetikaPlus to build a comprehensive database of drug information, which can be used to help doctors to select the most appropriate treatment for their patients.
These are just a few of the scientific achievements that GenetikaPlus has made in the last 12 months. The company is committed to staying at the forefront of precise medicine technology, and it is confident that it will continue to make significant contributions to the field in the years to come.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Overall, the potential impacts of RXMine are significant. The technology could revolutionize the way depression is treated, leading to better outcomes for patients and reducing the burden of the disease on society. Among the impacts:
• Reduce suffering: Currently, only 37% of patients respond to their first antidepressant medication. With RXMine, doctors more accurately predict which patients are likely to respond to a particular medication, leading to better outcomes for patients.
• Increased success rates of drug treatment: With RXMine, the success rate increases from 37% to 79% or higher, meaning that more patients would be able to find relief from their symptoms.
• Minimized adverse events by preventing prescription errors due to drug-drug interactions and contraindications: RXMine also helps to minimize adverse events by preventing prescription errors due to drug-drug interactions and contraindications.
• Improve success rates for physicians and reduce physician burnout: RXMine helps to improve success rates for physicians and reduce physician burnout. The technology would make it easier for physicians to find the right treatment for their patients, reducing the number of patients who do not respond to treatment and the amount of time physicians spend on trial-and-error.
• Assist providers and governments to reduce hospitalizations by making beds available for other patients: RXMine helps providers and governments to reduce hospitalizations, by making beds available for other patients.
• Save €5,000 per year per patient and up to €0.5Bn in total: The total economic impact of RXMine is significant. The company estimates that the technology could save €5,000 per year per patient, and up to €0.5Bn in total.

Genetika+ using AI and Brian-in-a-dish technology to find the best antidepressants for patients

Genetika+ presenting in 2023 American Psychiatric Association meeting (San Francisco).